How many investments has PureTech Health made?

PureTech Health has 5 tracked investments, 1 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.

What sectors does PureTech Health focus on?

PureTech Health focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is PureTech Health located?

PureTech Health is headquartered in Boston, US.

Does PureTech Health lead rounds?

PureTech Health typically participates in rounds rather than leading them.

Who does PureTech Health co-invest with?

PureTech Health most often shares deals with Sofinnova Ventures, ARCH Venture Partners, Foresite Capital, among 4 tracked co-investors.

PureTech Health

Venture studio

Boston · 11 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

PureTech Health builds and develops novel medicines by identifying patient needs where an existing therapeutic approach has demonstrated human efficacy but is held back by limitations such as off-target effects, low bioavailability, or poor tolerability. Its R&D model rests on three principles: validated efficacy, clear patient benefit, and an efficient, de-risked path to new classes of medicine. Programs are advanced through Founded Entities, exemplified by KarXT (Cobenfy) for schizophrenia, developed in Karuna Therapeutics and later acquired by Bristol Myers Squibb. Other programs include deupirfenidone for idiopathic pulmonary fibrosis and GlyphAllo, an oral allopregnanolone prodrug using its Glyph technology for mental health indications.

Invests inBiotech Digital Health Healthtech Medical Devices Boston United States

Source: firm website, verified Aug 7, 2026.

Boston, US

Leads rounds

Follows

Last 12 months

1 investment

Tracked investments

Team · 11 people

from the firm's website

Eric Elenko· Co-founder & President

Co-founder and president of PureTech who has led development of several programs, including three FDA-approved products (EndeavorRx, Plenity, Cobenfy), and co-founded Seaport Therapeutics. Formerly a consultant at McKinsey & Company.

Robert Langer· Co-Founder & Non-Executive Director

Co-founder and non-executive director of PureTech, David H. Koch Institute Professor at MIT, and one of the most prolific and cited inventors in medicine, serving on boards including Moderna.

Allison Mead Talbot· Senior Vice President, Communicationsin

SVP of communications at PureTech directing corporate, brand, internal communications, and investor and media relations since 2016. Previously worked at PR agencies TogoRun and Feinstein Kean Healthcare.

Charles (Chip) Sherwood· Chief Operating Officer & General Counsel

COO and general counsel at PureTech leading strategic, operational, and legal matters since 2021. Previously VP, Corporate Legal Counsel at Anika Therapeutics.

H. Robert Horvitz· Board Observer, R&D Committee Chair

Board observer and R&D Committee chair, Nobel laureate in Physiology or Medicine and David H. Koch Professor of Biology at MIT, and co-founder of multiple life science companies.

John LaMattina· Independent Non-Executive Directorin

Independent non-executive director since 2009 and former president of Pfizer Global Research and Development, serving on several biotech boards including Vedanta Biosciences and Immunome.

Kiran Mazumdar-Shaw· Independent Non-Executive Director

Independent non-executive director, pioneer of India's biotech industry, and founder of Biocon, who serves on boards including Infosys and Narayana Health.

Michael Inbar· Chief Accounting Officer

Chief accounting officer overseeing accounting, compliance, and finance operations at PureTech since 2023. Previously CFO of Acronis and interim CFO of Wallarm, with over 20 years of finance experience.

Michele Holcomb· Non-Executive Director, Audit Committee Member

Independent non-executive director and Audit Committee member with over 30 years of healthcare experience. Former EVP and Chief Strategy Officer at Cardinal Health and COO of Global R&D at Teva.

Robert Lyne· Chief Executive Officerin

CEO and board member of PureTech, previously CEO of Arix Bioscience plc. An experienced leader of UK-listed life science and venture capital companies who began his career as a lawyer at Bird & Bird before joining Touchstone Innovations.

Sharon Barber-Lui· Interim Chair of the Board of Directors, Audit Committee Memberin

Interim board chair and Audit Committee member at PureTech; CFO, North America for Teva Pharmaceuticals since 2023 and former SVP of Finance at EQRx, with over two decades of experience at Merck.

Founder mafia

2 people who came through PureTech Health went on to found or lead other companies.

David SteinbergCo-Founder and Chief Innovation OfficerFounded Restorbio +1 Raju KucherlapatiMember, BODFounded KEW Group

What they invest in

from 2 of 6 portfolio companies

Biotech ×2Medical Devices ×1Mental Health ×1

HQs:United States×1

Investments · 6 tracked

founders shown can be your intro path

By year:2026 · 1 2024 · 12 dated

Seaport Therapeuticsseaporttx.com in 𝕏NASDAQ: SPTXOct 2024

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO and Board Member)inMichael Chen(Executive Officer)Lana Gladstein(Executive Officer)Antony Loebel(Executive Officer)Eric Green(Executive Officer)

BoardJames I. Healy(Director)

Co-investorsARCH Venture Partners Foresite Capital HAWKTAIL Sofinnova Ventures

Celea Therapeuticsceleatx.com inJul 2026 · $180M

Celea is a biopharmaceutical company developing next-generation therapies for serious respiratory diseases, with a lead antifibrotic drug candidate, deupirfenidone, in Phase 3 development for idiopathic pulmonary fibrosis (IPF).

BiotechMedical Devices

Co-investorsRA Capital Leaps by Bayer

Celea Therapeutics

PureTech-founded entity advancing deupirfenidone (via the Phase 3 SURPASS-IPF trial) as a potential new standard of care for idiopathic pulmonary fibrosis.

Gallop Oncology

Karuna

Karuna Therapeutics

PureTech Founded Entity that developed KarXT (Cobenfy) for schizophrenia and was acquired by Bristol Myers Squibb for $14 billion.

Co-investorsSofinnova Ventures

Exits · 1

IPOs and acquisitions across the tracked portfolio

Seaport TherapeuticsNASDAQ: SPTX

Portfolio news

latest coverage across their companies

PureTech's Celea Raises $180m and Doses First Phase 3 Patient in IPF Trial

Celea Therapeutics · kalkine.co.uk · Aug 10, 2026

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - AOL

Seaport Therapeutics · aol.com · Jun 8, 2026

Frequently asked questions

How many investments has PureTech Health made?: PureTech Health has 5 tracked investments, 1 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.
What sectors does PureTech Health focus on?: PureTech Health focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is PureTech Health located?: PureTech Health is headquartered in Boston, US.
Does PureTech Health lead rounds?: PureTech Health typically participates in rounds rather than leading them.
Who does PureTech Health co-invest with?: PureTech Health most often shares deals with Sofinnova Ventures, ARCH Venture Partners, Foresite Capital, among 4 tracked co-investors.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M